Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Announces Financial Results and Business Update for the Quarter Ended September 30, 2020
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 16, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced
View HTML
Toggle Summary AGTC Reports Additional Positive Data from its Phase 1/2 Clinical Trial in Patients with X-Linked Retinitis Pigmentosa
- Durable improvements observed   in visual sensitivity and visual acuity over a wide dose-range with a favorable safety profile - - Recent FDA interactions clarify clinically meaningful improvement on microperimetry and no further comments or questions regarding the company’s pre-clinical or CMC
View HTML
Toggle Summary AGTC to Host Conference Call on November 11 at 8:00 am ET to Discuss XLRP 12-Month Data and Full 6-Month Data from Highest Dose Groups of its Ongoing Phase 1/2 Clinical Trial
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Nov. 10, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC to Participate in Cantor Fitzgerald Virtual Panel: Key Considerations for Gene Therapy Manufacturing and Platforms
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 21, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC to Present at Upcoming Virtual Conferences
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Oct. 08, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC Joins the My Retina Tracker® Program as a New Scientific Collaborator
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Oct. 07, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (AGTC), Blueprint Genetics, and Foundation Fighting Blindness , announce today that AGTC, a biotechnology company conducting human clinical trials of adeno-associated virus
View HTML
Toggle Summary AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trial, New Data on XLRP Higher Dose Group and Financial Results for the Fourth Quarter and Year Ended June 30, 2020
- Planned Phase 2/3 trial expected to include approximately 60 patients and a responder analysis based on at least 7 decibel improvement in visual sensitivity in at least 5 loci across two active dose groups and one control group - - Data from Group 5 supports use of higher dose level in Phase 2/3
View HTML
Toggle Summary AGTC to Participate at Upcoming Virtual Investor Conferences
GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Sept. 03, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company focused on developing adeno-associated virus (AAV) based gene therapies for the treatment of rare inherited diseases, today announced that
View HTML
Toggle Summary AGTC to Host Management Update on September 9 at 8:00 am ET to Discuss Planned Phase 2/3 XLRP Trial, Share Additional XLRP Data and Report Fourth Quarter and Fiscal Year End 2020 Financial Results
GAINESVILLE, Fla. and CAMBRIDGE, Mass. , Sept. 02, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced that
View HTML
Toggle Summary AGTC Announces Publication of Preclinical Data that Support the Ongoing Clinical Development of Its XLRP Gene Therapy Program
Preclinical studies validate the transgene and dosing used in the ongoing Phase 1/2 clinical trial in patients with XLRP due to mutations in the RPGR gene GAINESVILLE, Fla. , and CAMBRIDGE, Mass. , Aug. 25, 2020 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a
View HTML
Visionary science for life changing cures.